Modulating the Therapeutic Activity of ADCs & SMDCs With Engineered Cytokine Products

Time: 2:30 pm
day: Day Two


  • Understanding how the therapeutic activity of ADCs and SMDCs can be potentiated with certain antibody-cytokine fusion proteins
  • Illustrating how antibody-cytokine fusions, based on interleukin-2 and capable of selective localisation at the tumour site, are particularly effective in boosting the activity of ADCs and SMDCs
  • Discussing the role of NK cells and of T cells